Literature DB >> 23546370

Commentary.

Rodrigo Ramos-Zúñiga1.   

Abstract

Entities:  

Year:  2013        PMID: 23546370      PMCID: PMC3579068     

Source DB:  PubMed          Journal:  J Neurosci Rural Pract        ISSN: 0976-3155


× No keyword cloud information.
The neurocysticercosis is one of diseases affecting the nervous system with greater diversity and clinical complexity. The symptoms of this pathology are polymorphic and usually turn into a chronic disease pathology in their symptoms, and an evolution usually as a chronic disease. The case presented by Joshi et al. is a sample is a sample about it.[1] In the case of hydrocephalus secondary to the neurocysticercosis, basically concur two pathological phenomena. (a) The presence of cysticerci in different stages that determine mass effect and cause obstruction of CSF (cerebrospinal fluid) dynamics. (b) The inflammatory response, which affects changes in the wall ependymal, proliferation (ependymitis), and failures in the balance between production and absorption of CSF.[23] Any of these two events may cause hydrocephalus, and they may occur together, particularly whenever pharmacotherapy with rupture is performed and emptying the contents of the cysts into the ventricular cavity, or in the subarachnoid space (arachnoiditis). This can also happen during the rupture of cysts in the surgical process. Further, it is important to consider the interaction host-immune response to determine the risk-benefit balance of pharmacological treatment alone, particularly in patients with hydrocephalus, cysticerci in the subarachnoid space, or symptomatic mass effect.[4-7] It is important to consider that the endoscopic approach for cysticerci in the ventricular space is generally Accessible and currently documented as a diagnostic criterion through the “Full Moon” endoscopic sign.[8] However we need to think that cysticercosis is a general parasitic disease that affects potentially several organs, and has a life cycle in which the gastrointestinal role is relevant. Consequently it is important to consider the antihelminthic drug treatment as an adjuvant and complementary element in these cases, and after surgical resection in some other cases. As a result,as a not surprising” result, the neurocysticercosis can emulate any neurological syndrome, and that their evolutionary behavior and their consequential events, does not necessarily imply a new infestation, but a variation of the chronicity and progression of the disease. It is relevant as a public health problem, redirect preventive strategies, including considerations of human migration, which has turned it into a global disease, not just in underdeveloped countries. It will remain a therapeutic challenge, since so far advances in the pharmacological treatment and its accessibility have not been sufficient to establish definitive control. We have recently reviewed the relevance of antihelmintic treatment and its specific role, particularly in the case of parenchymal cysticercosis which has demonstrate a favorable risk-benefit balance to the antihelmintic treatment These treatment is useful as a primary therapy and non only as an option after of pharmacological treatment failure. However, it is different in the case of cysticerci racemosus, giants, cysticerci in the subarachnoid space, ventricular space, and with significant edema or mass effect related to parenchymatous level. Antihelmintic treatment should be handled with caution and be considered as complementary in these cases after the surgical treatment, in order to avoid a severe inflammatory reaction.[910] Pharmacological treatment alone is not harmless and requires an analysis about its relevance, dose, time management, and concurrency with surgical treatment, where has been considered this not necessarily must be an alternate present after the failure of pharmacological treatment. That may eventually be the first therapeutic alternative, through current minimally invasive techiques today, whereas through current minimally invasive techniques today.
  8 in total

1.  Impact of antihelminthic treatment in neurosurgical patients with symptomatic neurocysticercosis.

Authors:  Rodrigo Ramos-Zúñiga
Journal:  World Neurosurg       Date:  2011-11-30       Impact factor: 2.104

Review 2.  Neurocysticercosis: the enigmatic disease.

Authors:  Svetlana Agapejev
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2011-12-01

3.  Bruns' syndrome and racemose neurocysticercosis: a case report.

Authors:  Roberta Diehl Rodriquez; Denise Neme da Silva Crestani; José Otávio Dworzecki Soares; Paulo Roberto Franceshini; Ronnie Petersen Alves; Ricardo Zimerman; Nelson Ferreira; Liselotte Menke Barea
Journal:  Rev Soc Bras Med Trop       Date:  2012 Mar-Apr       Impact factor: 1.581

Review 4.  Hydrocephalus in neurocysticercosis.

Authors:  Hamilton Matushita; Fernando Campos Gomes Pinto; Daniel Dante Cardeal; Manoel Jacobsen Teixeira
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

5.  "Full moon" endoscopic sign in intraventricular neurocysticercosis.

Authors:  R Ramos-Zúñiga; J de La Cruz-Ramírez; P M Casillas-Espinosa; J A Sánchez-Prieto; M D S López-Hernández
Journal:  Minim Invasive Neurosurg       Date:  2011-06-07

Review 6.  Neurocysticercosis.

Authors:  Oscar H Del Brutto
Journal:  Continuum (Minneap Minn)       Date:  2012-12

7.  Comparison of cerebrospinal fluid obtained by ventricular endoscopy and by lumbar puncture in patients with hydrocephalus secondary to neurocysticercosis.

Authors:  Jaime G Torres-Corzo; J Humberto Tapia-Pérez; Martín Sánchez-Aguilar; Roberto Rodriguez Della Vecchia; Juan C Chalita Williams; Ricardo Cerda-Gutiérrez
Journal:  Surg Neurol       Date:  2009-03

8.  Repeated hydrocephalus in recurrent intraventricular neurocysticercosis: An uncommon presentation.

Authors:  Krishna C Joshi; Hukum Singh; Puja Sakhuja; Daljit Singh
Journal:  J Neurosci Rural Pract       Date:  2013-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.